Raymond Scott Turner, M. Hebron, A. Lawler
May 28, 2020
Citations
4
Influential Citations
64
Citations
Quality indicators
Journal
Annals of Neurology
Abstract
Preclinical evidence with nilotinib, a US Food and Drug Administration (FDA)‐approved drug for leukemia, indicates improvement in Alzheimer's disease phenotypes. We investigated whether nilotinib is safe, and detectable in cerebrospinal fluid, and alters biomarkers and clinical decline in Alzheimer's disease.